FDA
-
-
-
-
-
-
-
Glaukos Announces Participation in Upcoming Investor Conferences
-
-
-
-
-
-
-
Glaukos Announces Commercial Availability of Epioxaâ„¢, a Transformative Innovation in Interventional Keratoconus Care
-
-
-
-
-
-
-
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
-
-
-
-
-
-
-
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
-
-
-
-
-
-
-
Glaukos Corporation (GKOS) Announces EU MDR Certification for iStent infinite and Other Leading MIGS Therapies
-
-
-
-
-
-
-
Glaukos Announces the Release of its 2024 Sustainability Report
-
-
-
-
-
-
-
Glaukos Corporation (GKOS) Announces Positive Clinical Updates for its iDose Sustained-Release Procedural Pharmaceutical Platform
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

